Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.7800
Dollar change
0.0000
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.45 Insider Own25.51% Shs Outstand27.11M Perf Week1.83%
Market Cap21.15M Forward P/E- EPS next Y-1.13 Insider Trans0.00% Shs Float20.20M Perf Month11.21%
Income-38.35M PEG- EPS next Q-0.35 Inst Own5.20% Short Float0.09% Perf Quarter9.21%
Sales0.00M P/S- EPS this Y35.80% Inst Trans0.53% Short Ratio0.07 Perf Half Y11.75%
Book/sh1.19 P/B0.65 EPS next Y27.56% ROA-68.84% Short Interest0.02M Perf Year-59.38%
Cash/sh1.22 P/C0.64 EPS next 5Y47.60% ROE-81.52% 52W Range0.50 - 3.70 Perf YTD8.33%
Dividend Est.- P/FCF- EPS past 5Y-14.07% ROI-118.37% 52W High-78.92% Beta1.25
Dividend TTM- Quick Ratio6.31 Sales past 5Y0.00% Gross Margin- 52W Low56.00% ATR (14)0.07
Dividend Ex-Date- Current Ratio6.31 EPS Y/Y TTM40.13% Oper. Margin0.00% RSI (14)52.64 Volatility7.07% 10.83%
Employees13 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price2.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q56.49% Payout- Rel Volume0.47 Prev Close0.78
Sales Surprise- EPS Surprise30.12% Sales Q/Q- Earnings- Avg Volume275.05K Price0.78
SMA20-1.97% SMA509.81% SMA200-27.28% Trades Volume128,972 Change0.00%
Date Action Analyst Rating Change Price Target Change
Apr-26-21Resumed Credit Suisse Outperform $12
Nov-23-20Initiated SVB Leerink Outperform $27
Nov-23-20Initiated Credit Suisse Outperform $29
Nov-23-20Initiated BofA Securities Buy $21
Mar-15-24 01:53PM
Feb-14-24 12:00PM
Jan-09-24 04:57PM
Dec-22-23 06:52AM
Dec-21-23 04:05PM
08:00AM Loading…
Oct-23-23 08:00AM
Sep-28-23 09:49AM
Sep-27-23 05:08AM
Sep-26-23 04:01PM
Aug-31-23 11:00AM
Aug-17-23 07:01PM
08:58AM
Aug-16-23 07:46AM
Aug-15-23 07:35AM
07:30AM
04:05PM Loading…
Jul-31-23 04:05PM
Jul-27-23 11:02PM
Jul-25-23 09:59AM
Jun-20-23 08:58AM
May-30-23 08:00AM
May-23-23 08:30AM
May-20-23 08:54AM
May-17-23 04:01PM
Apr-28-23 08:00AM
Apr-13-23 08:30AM
Mar-09-23 07:00AM
Mar-02-23 04:05PM
Feb-01-23 08:00AM
Dec-11-22 07:36AM
Dec-07-22 04:05PM
09:55AM Loading…
Nov-24-22 09:55AM
Nov-11-22 12:00PM
Nov-08-22 09:15AM
06:00AM
Nov-03-22 08:00AM
Oct-31-22 08:00AM
Oct-19-22 08:00AM
Oct-17-22 06:00AM
Sep-29-22 11:17AM
06:00AM
Sep-06-22 08:30AM
Aug-29-22 08:30AM
Jul-29-22 09:00AM
Jul-03-22 08:17AM
Jun-16-22 08:00AM
May-31-22 08:30AM
May-26-22 08:30AM
May-02-22 08:30AM
Apr-29-22 08:57AM
Apr-26-22 08:30AM
Mar-29-22 08:30AM
Mar-25-22 10:25AM
Mar-15-22 11:10AM
Mar-10-22 11:05AM
Mar-09-22 10:49AM
Mar-04-22 10:00AM
Feb-17-22 05:00PM
Feb-07-22 08:00AM
Jan-27-22 07:00AM
Jan-24-22 05:56AM
Jan-19-22 09:38PM
Jan-05-22 08:00AM
Dec-20-21 08:00AM
Dec-13-21 08:00AM
Nov-04-21 04:30PM
Nov-02-21 11:26AM
08:00AM
01:14AM
Oct-28-21 08:00AM
Oct-26-21 08:00AM
Sep-15-21 08:30AM
Sep-13-21 08:00AM
Aug-18-21 09:25AM
08:00AM
Aug-05-21 08:30AM
Jul-28-21 04:31AM
Jul-13-21 08:00AM
Jun-22-21 12:40PM
09:27AM
Jun-10-21 03:31PM
Jun-02-21 08:00AM
May-11-21 08:00AM
May-06-21 08:00AM
May-04-21 08:30AM
Apr-29-21 05:49AM
Apr-19-21 06:38AM
Apr-15-21 08:00AM
Mar-29-21 08:30AM
Mar-23-21 10:26AM
08:30AM
Mar-15-21 07:30AM
Feb-09-21 08:00AM
Jan-29-21 01:33AM
Jan-08-21 08:00AM
Jan-04-21 04:01PM
Dec-11-20 08:06AM
Nov-30-20 08:00AM
Nov-23-20 04:01PM
Oct-29-20 01:28PM
Oct-28-20 09:10PM
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLC10% OwnerAug 15 '23Sale0.75822,680617,01097,204Aug 17 04:40 PM
ORBIMED ADVISORS LLC10% OwnerJul 31 '23Sale3.00209,400628,200135,531Aug 02 05:05 PM
ORBIMED ADVISORS LLC10% OwnerJul 25 '23Sale2.9239,200114,464162,153Jul 27 04:28 PM
ORBIMED ADVISORS LLC10% OwnerJul 13 '23Sale2.40194,700467,280169,953Jul 17 04:13 PM
ORBIMED ADVISORS LLC10% OwnerApr 17 '23Sale1.9713,08925,785179,753Apr 17 05:28 PM
ORBIMED ADVISORS LLC10% OwnerApr 14 '23Sale1.8641,44677,090180,413Apr 17 05:28 PM
ORBIMED ADVISORS LLC10% OwnerApr 13 '23Sale1.8213,94625,382182,504Apr 17 05:28 PM
ORBIMED ADVISORS LLC10% OwnerApr 12 '23Sale1.812,3634,277183,207Apr 12 06:44 PM
ORBIMED ADVISORS LLC10% OwnerApr 11 '23Sale1.8213,94625,382183,326Apr 12 06:44 PM
ORBIMED ADVISORS LLC10% OwnerApr 10 '23Sale1.7951,22891,698185,910Apr 12 06:44 PM
ORBIMED ADVISORS LLC10% OwnerApr 06 '23Sale2.009,66519,330186,613Apr 07 04:42 PM
ORBIMED ADVISORS LLC10% OwnerApr 05 '23Sale2.1892,965202,664187,100Apr 07 04:42 PM